|Day's Range||74.05 - 75.41|
|52 Week Range||65.47 - 99.14|
|PE Ratio (TTM)||-3.16|
|Dividend & Yield||0.64 (0.87%)|
|1y Target Est||N/A|
Health care stocks got a lift Thursday after Senate Republicans rolled out their proposed bill to repeal Obamacare.
After Dupixent's commercial launch, Regeneron has been involved in creating awareness for the drug among physicians who have been treating AD patients.
Shares of specialty pharmaceutical companies, including Valeant Pharmaceuticals International (VRX), Horizon Pharma (HZNP), Perrigo (PRGO), and Mallinckrodt (MNK), have been under pressure for a while now, as investors have remained focused on their business models of raising prices. In offering her upbeat view on specialty-pharmaceutical companies, Chen recommends investors to not "look back, because objects in the rearview mirror can appear closer than they are." In fact, she claims that management has already started to pivot from the old model of constantly rising prices, and the ones that can "innovate and/or save the healthcare system money can thrive under the new order." Chen initiated coverage on Aclaris Therapeutics (ACRS), Horizon Pharma, Impax Laboratories (IPXL), Mallinckrodt, Perrigo, Theravance Biopharma (TBPH), Valeant, Zoetis (ZTS), and Shire (SHPG), which she calls her "highest conviction recommendation.